# FDA Advisory Panel

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/fda-advisory-panel
Canonical HTML page: https://gethealthbrief.com/entity/fda-advisory-panel

## Timeline

- **2026-08-05**: FDA final decision deadline — The agency must decide whether to approve the first mRNA-based influenza vaccine, with major implications for the platform’s future.
- **2026-06**: Advisory panel recommends approval — The FDA’s Vaccines and Related Biological Products Advisory Committee votes to recommend the mRNA flu shot for licensure.
- **2026-02**: FDA refuses to review Moderna’s mRNA flu vaccine — FDA sends a refusal-to-file letter, stunning Moderna executives. Moderna had prior indications that a review would proceed.
- **2026-02**: FDA reverses decision after industry backlash — About a week later, FDA agrees to review the application after Moderna commits to a confirmatory post-market study, following public outcry and pressure.

## Recent coverage (1 stories)

### FDA's Aug. 5 decision on first mRNA flu shot could reshape $5B flu market
2026-08-01 14:59:02 · Sentiment: Neutral · Impact: 6/10 · Sources: 3

The FDA’s imminent decision on Moderna’s mRNA flu vaccine carries high stakes for healthcare providers and the vaccine industry. While an advisory panel backed approval, political skepticism from HHS Secretary RFK Jr. and a prior agency reversal add uncertainty. The ruling could either accelerate or stall mRNA’s expansion beyond COVID-19.
Full story: https://gethealthbrief.com/story/fda-mrna-flu-shot-health-regulation

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.